Flagship Pioneering is an investment fund managing more than $2.38 billion ran by Noubar Ph.d.. There are currently 12 companies in Ph.d.’s portfolio. The largest investments include Moderna Inc and Sana Biotechnology Inc, together worth $1.73 billion.
As of 7th November 2022, Flagship Pioneering’s top holding is 12,886,743 shares of Moderna Inc currently worth over $1.52 billion and making up 64.1% of the portfolio value.
Relative to the number of outstanding shares of Moderna Inc, Flagship Pioneering owns more than approximately 0.1% of the company.
In addition, the fund holds 34,239,018 shares of Sana Biotechnology Inc worth $205 million.
The third-largest holding is Seres Therapeutics Inc worth $148 million and the next is Omega Therapeutics Inc worth $140 million, with 25,902,269 shares owned.
Currently, Flagship Pioneering's portfolio is worth at least $2.38 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Flagship Pioneering office and employees reside in Cambridge, Massachusetts. According to the last 13-F report filed with the SEC, Noubar Ph.d. serves as the Chief Executive Officer at Flagship Pioneering.
In the most recent 13F filing, Flagship Pioneering revealed that it had opened a new position in
Syros Pharmaceuticals and bought 993,848 shares worth $6.4 million.
This means they effectively own 0.2% of the company.
Syros Pharmaceuticals makes up
0.3%
of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.
The investment fund also strengthened its position in Seres Therapeutics Inc by buying
8,738,243 additional shares.
This makes their stake in Seres Therapeutics Inc total 23,117,045 shares worth $148 million.
Seres Therapeutics Inc dropped approximately 0.1% in the past year.
On the other hand, there are companies that Flagship Pioneering is getting rid of from its portfolio.
Flagship Pioneering closed its position in Syros Pharmaceuticals on 14th November 2022.
It sold the previously owned 2,938,494 shares for $2.82 million.
The two most similar investment funds to Flagship Pioneering are Laurion Capital Management L.P. and Suvretta Capital Management. They manage $2.38 billion and $2.37 billion respectively.
Flagship Pioneering’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 85.4% of
the total portfolio value.
The fund focuses on investments in the United States as
83.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
42% of the total holdings value.
On the other hand, large-cap stocks make up only 8.3% of the portfolio.
The average market cap of the portfolio companies is close to $7.51 billion.
These positions were updated on November 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Moderna Inc |
No change
12,886,743
|
$1,523,857,000 | 64.14% |
| Sana Biotechnology Inc |
No change
34,239,018
|
$205,434,000 | 8.65% |
| Seres Therapeutics Inc |
60.77%
23,117,045
|
$148,411,000 | 6.25% |
| Omega Therapeutics Inc |
No change
25,902,269
|
$140,391,000 | 5.91% |
| Foghorn Therapeutics Inc. |
No change
12,674,120
|
$108,744,000 | 4.58% |
| Evelo Biosciences Inc |
No change
50,427,328
|
$105,393,000 | 4.44% |
| Denali Therapeutics Inc |
No change
2,619,968
|
$80,407,000 | 3.38% |
| Axcella Health Inc |
No change
18,867,785
|
$32,264,000 | 1.36% |
| Rubius Therapeutics Inc |
No change
38,506,526
|
$16,557,000 | 0.70% |
| Syros Pharmaceuticals Inc. |
Opened
993,848
|
$6,400,000 | 0.27% |
| Sigilon Therapeutics, Inc. |
No change
10,370,369
|
$5,185,000 | 0.22% |
| Syros Pharmaceuticals Inc. |
Closed
2,938,494
|
$2,821,000 | |
| Codiak BioSciences, Inc. |
35.80%
3,540,636
|
$2,762,000 | 0.12% |
| No transactions found | |||
| Showing first 500 out of 13 holdings | |||